110
Participants
Start Date
September 10, 2013
Primary Completion Date
January 8, 2020
Study Completion Date
January 8, 2020
PF-05212384 (gedatolisib)
PF-05212384 weekly intravenous infusions starting at 90 mg/wk as a 3 week cycle
Docetaxel
Docetaxel intravenous infusions once every 3 weeks starting at 75 mg/m\^2
Cisplatin
Cisplatin intravenous infusions once every 3 weeks starting at 75 mg/m\^2
Dacomitinib
Dacomitinib to be taken orally as a continuous once daily regimen at a starting dose of 30 mg
Fox Chase Cancer Center, Philadelphia
Istituto Europeo di Oncologia - Divisione Sviluppo di Nuovi Farmaci per Terapie Innovative, Milan
Hospital Universitario 12 de Octubre, Madrid
MUSC Specialty Care-North, North Charleston
Medical University of South Carolina/ University Hospital, Charleston
Medical University of South Carolina, Charleston
MUSC SCTR Research, Charleston
MUSC Health East Cooper, Mt. Pleasant
University of Alabama at Birmingham, Birmingham
University of Alabama at Birmingham, Birmingham
Harper Professional Building, Detroit
Karmanos Cancer Institute, Detroit
University of Colorado Denver CTO (CTRC), Aurora
University of Colorado Hospital, Aurora
Ronald Reagan UCLA Medical Center, Los Angeles
UCLA Hematology Oncology, Los Angeles
Westwood Bowyer Clinic, Los Angeles
Santa Monica UCLA Medical Center & Orthopaedic Hospital, Santa Monica
UCLA Hematology Oncology, Santa Monica
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
Brigham and Women's Hospital, Boston
Beth Israel Deaconess Medical Center, Boston
Dana Farber Cancer Institute, Boston
British Columbia Cancer Agency - Vancouver Centre, Vancouver
Princess Margaret Cancer Center, Toronto
Istituto Regina Elena Struttura Complessa Oncologia Medica A, Roma
Hospital Universitari Vall d'Hebron, Barcelona
University College London Hospital, NIHR UCLH Clinical Research Facility, London
Oxford Cancer Centre, Oxford
Lead Sponsor
Pfizer
INDUSTRY